Abstract:Targeted protein degradation using small molecules is a novel strategy for drug development. In order to solve the problem of drug resistance in the treatment of prostate cancer, proteolysis-targeting chimeras (PROTAC) was introduced into the design of anti-prostate cancer derivatives. In this work, we synthesized two series of selective androgen receptor degraders (SARDs) containing the hydrophobic degrons with different linker, and then investigated the structure-activity relationships of these hybrid compounds. Most of the synthesized compounds exhibited moderate to good activity against all the cancer cell lines selected. Among them, compound A9 displayed potent inhibitory activity against LNCaP prostate cancer cell line with IC50 values of 1.75 μM, as well as excellent AR degradation activity. Primary mechanism studies elucidated compound A9 arrested cell cycle at G0/G1 phase and induced a mild apoptotic response in LNCaP cells. Further study indicated that the degradation of AR was mediated through proteasome-mediated process. For all these reasons, compound A9 held promising potential as anti-proliferative agent for the development of highly efficient SARDs for drug-resistance prostate cancer therapies.

What problem does this paper attempt to address?

This paper attempts to solve the problem of drug resistance in prostate cancer treatment. Specifically, the author explored the degradation effect of these compounds on androgen receptor (AR) and their anti - tumor mechanisms by designing and synthesizing two series of selective androgen receptor degraders (SARDs). The main goal of the paper is to develop efficient SARDs to overcome the drug resistance problems encountered in existing treatment methods for castration - resistant prostate cancer (CRPC). ### Background of the paper Prostate cancer (PCa) is one of the most common male malignancies and the second leading cause of cancer death in men in developed countries. Currently, the main treatment for advanced prostate cancer is androgen deprivation therapy (ADT), but its clinical effect is limited. Especially for castration - resistant prostate cancer (CRPC), existing treatment methods are often ineffective and prone to drug resistance. Therefore, finding new treatment targets and molecular modulators is crucial for the treatment of CRPC. ### Research methods 1. **Compound design and synthesis**: - The author designed and synthesized two series of selective androgen receptor degraders (SARDs), which contain different linker groups and hydrophobic degrons. - The target compounds were synthesized by click reaction and the structure was optimized. 2. **Bioactivity evaluation**: - **AR binding affinity**: The binding affinity of the compounds to AR was evaluated by fluorescence polarization (FP) competition experiment. - **Cell proliferation inhibitory activity**: The cell proliferation inhibitory activity of the compounds on different cell lines (LNCaP, C4 - 2B, PC - 3 and WPMY - 1) was detected by SRB (Sulforhodamine B) method. - **Cell cycle arrest**: The effect of compound A9 on the cell cycle of LNCaP cells was analyzed by flow cytometry. - **Apoptotic effect**: The effect of compound A9 on the apoptosis of LNCaP cells was detected by Annexin V/PI staining method. - **AR degradation**: The effect of compound A9 on the AR protein level was evaluated by Western blot experiment, and the mechanism of AR degradation was further explored. ### Main findings - **Compound A9** showed the strongest inhibitory activity, with an IC50 value of 1.75 μM for LNCaP cells, and had excellent AR degradation activity. - **Cell cycle arrest**: Compound A9 was able to arrest LNCaP cells in the G0/G1 phase in a concentration - dependent manner. - **Apoptosis induction**: Compound A9 was able to induce the apoptosis of LNCaP cells, and the total apoptosis rate increased from 2.76% to 19.22%. - **AR degradation mechanism**: Compound A9 mediates the degradation of AR through the proteasome pathway without affecting the levels of other steroid receptors such as progesterone receptor (PR). - **Molecular docking study**: Through molecular docking analysis, the interaction mode between compound A9 and AR was revealed, especially the key role of its hydrophobic side chain in AR degradation. ### Conclusion This study successfully designed and synthesized SARDs with high - efficiency AR degradation activity. In particular, compound A9 showed excellent anti - tumor activity and AR selectivity. These findings provide new possibilities for developing new SARDs to overcome the drug resistance of CRPC.

The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader

Synthesis and Modeling of Novel Α-Aminoalkylphosphonate Ester Derivatives As Potent Inhibitors of Prostate-Specific Antigen; A Comparison Study

Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment

The Design, Synthesis and Bioactivity Evaluation of Novel Androgen Receptor Degraders Based on Hydrophobic Tagging

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer

Strategies Toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer

Discovery of ARD-2051 As a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer

Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer

Discovery of N -(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2

Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

Design, synthesis and biological evaluation of dual inhibitors targeting AR/AR-Vs and PARP1 in castration resistant prostate cancer therapy

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

Abstract LB133: An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer

1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells

First small-molecule PROTACs for G protein-coupled receptors: inducing 1A-adrenergic receptor degradation